

Julia Stomper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4243161/publications.pdf>

Version: 2024-02-01

7
papers

167
citations

1684188
5
h-index

1720034
7
g-index

7
all docs

7
docs citations

7
times ranked

170
citing authors

#	ARTICLE	IF	CITATIONS
1	Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the <i>TRIB2</i> and <i>ABCB6</i> genes. <i>Blood Advances</i> , 2022, , .	5.2	1
2	Decitabine Induces Gene Derepression on Monosomic Chromosomes: <i>In Vitro</i> and <i>In Vivo</i> Effects in Adverse-Risk Cytogenetics AML. <i>Cancer Research</i> , 2021, 81, 834-846.	0.9	18
3	Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients. <i>Clinical Epigenetics</i> , 2021, 13, 77.	4.1	14
4	Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. <i>Leukemia</i> , 2021, 35, 1873-1889.	7.2	104
5	Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine. <i>British Journal of Haematology</i> , 2020, 189, e194-e197.	2.5	1
6	Can we predict responsiveness to hypomethylating agents in AML?. <i>Seminars in Hematology</i> , 2019, 56, 118-124.	3.4	15
7	Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. <i>Haematologica</i> , 2019, 104, 59-69.	3.5	14